Serum Hypoxia Inducible Factor-2: A Candidate Prognostic Bio
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
According to a recent study by Clinical Otolaryngology, serum hypoxia inducible factor-2 is an important biomarker for the prognosis of laryngeal cancer.

The researcher determined the serum hypoxia inducible factor-1, -2, and -3 (HIF-1, -2, and -3) levels in patients with laryngeal neoplasm, and investigate their role in differential diagnosis, prediction of tumor characteristic and extension, and prognosis and survival.

Patients with benign, premalignant, and malignant laryngeal neoplasms were included. Sixty-four patients with a laryngeal neoplasm were enrolled.

--A statistically significant difference between benign, premalignant, and malignant laryngeal neoplasms was not detected when serum HIF-1, -2, and -3 levels were compared.

--However, high serum HIF-2 level adversely affected survival, and locoregional control and had more than a 7-fold increase in hazard ratio.

--Moreover, serum HIF-2 was an independent prognostic factor for 2-year overall-, disease-free-, distant metastasis-free survival and locoregional control.

In particular, hypoxia inducible factor-2 is a prognostic factor in larynx cancer irrespective of treatment modality.

Source: https://doi.org/10.1111/coa.13789
Like
Comment
Share